Zinnet Şevval Aksoyalp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zinnet Şevval Aksoyalp has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Gizem Kayki-Mutlu
Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye
6 shared publications - Leszek Wojnowski
Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
6 shared publications - Martin Christian Michel
Department of Pharmacology, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany
6 shared publications - Aybala Temel
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Türkiye
4 shared publications - Betül Rabia Erdoğan
İzmir Katip Çelebi Üniversitesi
3 shared publications - Saliha Aksun
İzmir Katip Çelebi Üniversitesi
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Folia Microbiologica
- Vol. 71 (4) , 847-861
Effects of empagliflozin and metformin on biofilm formation and pathogenicity factors of urinary Escherichia coli isolates
Escherichia coli , a major cause of urinary tract infections (UTIs), forms biofilms that contribute to antimicrobial resistance. Antidiabetic medications have gained attention for their potential antimicrobial effects, though data remain limited. This study investigated the inhibitory effects of empagliflozin and metformin against urinary E. coli isolates. Minimum inhibitory concentrations (MICs) were determined via broth microdilution, and synergistic interactions were assessed using the checkerboard method. Biofilm inhibition at sub-inhibitory drug concentrations was evaluated spectrophotometrically, and gene expression of fimH and luxS , were analyzed using RT-qPCR. Empagliflozin and metformin inhibited bacterial growth, with MICs ranging from 3.12–6.25 mg/mL and 25–50 mg/mL, respectively. A synergistic effect was observed in two isolates. Both drugs significantly reduced biofilm formation (51.8–72.9%) and downregulated fimH and luxS gene expression ( p < 0.01). This study showed that empagliflozin and metformin could have inhibitory effects against urinary E. coli isolates , supporting their potential in drug repurposing strategies. Empagliflozin and metformin demonstrated significant dose-dependent in vitro antivirulence and antibiofilm activities, further supported by the downregulation of key virulence-associated genes ( fimH and luxS ). To the best of our knowledge, this is the first report investigating the in vitro effects of empagliflozin against urinary E. coli isolates, and further investigation is required to determine the impact of antidiabetic medications on E. coli.
- 3 June 2026
- Published by Springer Nature in Folia Microbiologica
- Vol. 71 (4) , 847-861
Open AccessEffects of empagliflozin and metformin on biofilm formation and pathogenicity factors of urinary Escherichia coli isolates
Escherichia coli , a major cause of urinary tract infections (UTIs), forms biofilms that contribute to antimicrobial resistance. Antidiabetic medications have gained attention for their potential antimicrobial effects, though data remain limited. This study investigated the inhibitory effects of empagliflozin and metformin against urinary E. coli isolates. Minimum inhibitory concentrations (MICs) were determined via broth microdilution, and synergistic interactions were assessed using the checkerboard method. Biofilm inhibition at sub-inhibitory drug concentrations was evaluated spectrophotometrically, and gene expression of fimH and luxS , were analyzed using RT-qPCR. Empagliflozin and metformin inhibited bacterial growth, with MICs ranging from 3.12–6.25 mg/mL and 25–50 mg/mL, respectively. A synergistic effect was observed in two isolates. Both drugs significantly reduced biofilm formation (51.8–72.9%) and downregulated fimH and luxS gene expression ( p < 0.01). This study showed that empagliflozin and metformin could have inhibitory effects against urinary E. coli isolates , supporting their potential in drug repurposing strategies. Empagliflozin and metformin demonstrated significant dose-dependent in vitro antivirulence and antibiofilm activities, further supported by the downregulation of key virulence-associated genes ( fimH and luxS ). To the best of our knowledge, this is the first report investigating the in vitro effects of empagliflozin against urinary E. coli isolates, and further investigation is required to determine the impact of antidiabetic medications on E. coli.
- 31 May 2026
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 10 (2) , 240-249
Diet-Derived Trimethylamine N-Oxide (TMAO) Pathway Disruption in Patients with Concurrent Alcohol Use Disorder and Smokers Persists After Alcohol Detoxification
Background and Purpose: Trimethylamine N-oxide (TMAO), a gut-microbiota-derived metabolite, is associated with cardiometabolic diseases, and therapeutic strategies targeting TMAO reduction are gaining interest for disease management. This study aimed to compare serum TMAO levels in patients with alcohol use disorder (AUD) and smokers versus healthy controls, and to assess changes following medically supervised alcohol detoxification.Method: Demographic data, biochemical parameters, and serum TMAO levels were analyzed. These parameters were quantified in healthy controls and patients with AUD and smokers before and after alcohol detoxification.Results: The study included thirty-four healthy controls (six females and 28 males) and thirty-three patients (five females and 28 males) with AUD and smokers. At baseline, patients demonstrated significantly lower TMAO levels but higher levels of ferritin, CRP, AST, ALT, GGT, and MCV compared to healthy controls. Following detoxification, patients exhibited a further decrease in TMAO levels (p=0.024), alongside significant improvements in hepatic enzymes (AST and GGT) and ferritin levels (p
- 31 May 2026
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 10 (2) , 240-249
Diet-Derived Trimethylamine N-Oxide (TMAO) Pathway Disruption in Patients with Concurrent Alcohol Use Disorder and Smokers Persists After Alcohol Detoxification
Background and Purpose: Trimethylamine N-oxide (TMAO), a gut-microbiota-derived metabolite, is associated with cardiometabolic diseases, and therapeutic strategies targeting TMAO reduction are gaining interest for disease management. This study aimed to compare serum TMAO levels in patients with alcohol use disorder (AUD) and smokers versus healthy controls, and to assess changes following medically supervised alcohol detoxification.Method: Demographic data, biochemical parameters, and serum TMAO levels were analyzed. These parameters were quantified in healthy controls and patients with AUD and smokers before and after alcohol detoxification.Results: The study included thirty-four healthy controls (six females and 28 males) and thirty-three patients (five females and 28 males) with AUD and smokers. At baseline, patients demonstrated significantly lower TMAO levels but higher levels of ferritin, CRP, AST, ALT, GGT, and MCV compared to healthy controls. Following detoxification, patients exhibited a further decrease in TMAO levels (p=0.024), alongside significant improvements in hepatic enzymes (AST and GGT) and ferritin levels (p
- Open Access
- 11 March 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11157-11179
A year in pharmacology: new drugs approved by the US food and drug administration in 2025
The US Food and Drug Administration approved 45 new drugs and 4 new cellular and gene therapy products in 2025, that is, a total of 49 new medical therapies. Oncology, hematology/immunotherapy, and cardiovascular/respiratory drugs remain most frequent. Among oncology drugs, there is a trend for targeting ever smaller subtypes of malignancies and/or rarer malignancies. Trends over the past 6 years include steady levels of first-in-indication (about 10%), first-in-class (about 38%), and next-in-class (about 51%) approvals. Along with a large share of approvals in orphan indications (> 50%), fast track approval pathways are now regularly representing more than half of all new approvals. While small molecules remain the bedrock of novel medical treatments (about 60%), there is a growing segment of mRNA, gene, and cell-based pharmacological approaches. These data testify to the innovative strength of academia, biotechnology, and established pharmaceutical companies in providing innovative treatments, often related to previously unmet medical needs.
- 11 March 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11157-11179
Open AccessA year in pharmacology: new drugs approved by the US food and drug administration in 2025
The US Food and Drug Administration approved 45 new drugs and 4 new cellular and gene therapy products in 2025, that is, a total of 49 new medical therapies. Oncology, hematology/immunotherapy, and cardiovascular/respiratory drugs remain most frequent. Among oncology drugs, there is a trend for targeting ever smaller subtypes of malignancies and/or rarer malignancies. Trends over the past 6 years include steady levels of first-in-indication (about 10%), first-in-class (about 38%), and next-in-class (about 51%) approvals. Along with a large share of approvals in orphan indications (> 50%), fast track approval pathways are now regularly representing more than half of all new approvals. While small molecules remain the bedrock of novel medical treatments (about 60%), there is a growing segment of mRNA, gene, and cell-based pharmacological approaches. These data testify to the innovative strength of academia, biotechnology, and established pharmaceutical companies in providing innovative treatments, often related to previously unmet medical needs.
- 8 November 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 228, 112306
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for therapeutic radiopharmaceuticals
- 8 November 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 228, 112306
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) for therapeutic radiopharmaceuticals
- Open Access
- 31 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (5) , 5077-5099
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
The US Food and Drug Administration approved 50 new drugs and nine new cellular and gene therapy products in 2024, i.e., a total of 59 new medical therapies. The latter group represented three treatments each for oncology and hematology/immunotherapy, and one each for neurology, genetic disorders, and cardiovascular disorders. Oncology, hematology/immunotherapy, and neurological disorders (14, six, and seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe a greater share in first-in-class medications, more fast-track approvals, and mRNA/gene/cell-based therapies. While small molecules remain the largest fraction, their percentage has been declining substantially over the past 5 years. Taking together, these findings testify to the commitment of the pharmaceutical industry for innovative treatments, including conditions for which no approved therapies existed. On the other hand, there also is a trend for approvals for narrowly focused conditions such as tumors defined by genetic alterations.
- 31 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (5) , 5077-5099
Open AccessA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
The US Food and Drug Administration approved 50 new drugs and nine new cellular and gene therapy products in 2024, i.e., a total of 59 new medical therapies. The latter group represented three treatments each for oncology and hematology/immunotherapy, and one each for neurology, genetic disorders, and cardiovascular disorders. Oncology, hematology/immunotherapy, and neurological disorders (14, six, and seven, respectively) also were highly prevalent among classic medications. Looking at trends over the past 5 years, we observe a greater share in first-in-class medications, more fast-track approvals, and mRNA/gene/cell-based therapies. While small molecules remain the largest fraction, their percentage has been declining substantially over the past 5 years. Taking together, these findings testify to the commitment of the pharmaceutical industry for innovative treatments, including conditions for which no approved therapies existed. On the other hand, there also is a trend for approvals for narrowly focused conditions such as tumors defined by genetic alterations.
- 5 February 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (1) , 174-183
Trimethylamine N-oxide as a potential prognostic biomarker for mortality in patients with COVID-19 disease
- 5 February 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (1) , 174-183
Trimethylamine N-oxide as a potential prognostic biomarker for mortality in patients with COVID-19 disease
- 19 November 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (11) , e70018
Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
Objectives: The aim of this study was to conduct a comparative analysis of the proportion of cardiovascular adverse events (AEs) associated with the utilization of memantine and cholinesterase inhibitors and to highlight the potential impact of sex differences in these AEs.Methods: Cardiac and vascular disorders AEs with antidementia medications were obtained from the FDA Adverse Event Reporting System database. The reporting odds ratio and its corresponding 95% confidence intervals were calculated. The chi‐squared test was used to evaluate differences in categorical variables, and a two‐way ANOVA followed by a Bonferroni post‐test was used to compare the AEs reported for antidementia medications.Results: Memantine was associated with 544 selected cardiac and vascular disorder AEs. A signal for bradycardia, myocardial infarction, atrial fibrillation and cardiac arrest has been observed in patients receiving choline esterase inhibitors compared to those receiving memantine. On the other hand, cardiac failure and deep vein thrombosis AEs were found to be more common in patients receiving memantine. The majority of reported cardiac and vascular AEs were reported more frequently in female patients. More cases of cardiac failure, cardiac arrest, and deep vein thrombosis were reported in females than males taking memantine, but bradycardia was more common in males than females.Conclusion: Healthcare professionals should be aware of the potential for cardiovascular AEs during treatment with antidementia medications and the possibility of sex differences in this regard. Memantine differs from cholinesterase inhibitors in terms of cardiovascular AEs, and there may be sex‐related differences in the proportion of these AEs.
- 19 November 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (11) , e70018
Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
Objectives: The aim of this study was to conduct a comparative analysis of the proportion of cardiovascular adverse events (AEs) associated with the utilization of memantine and cholinesterase inhibitors and to highlight the potential impact of sex differences in these AEs.Methods: Cardiac and vascular disorders AEs with antidementia medications were obtained from the FDA Adverse Event Reporting System database. The reporting odds ratio and its corresponding 95% confidence intervals were calculated. The chi‐squared test was used to evaluate differences in categorical variables, and a two‐way ANOVA followed by a Bonferroni post‐test was used to compare the AEs reported for antidementia medications.Results: Memantine was associated with 544 selected cardiac and vascular disorder AEs. A signal for bradycardia, myocardial infarction, atrial fibrillation and cardiac arrest has been observed in patients receiving choline esterase inhibitors compared to those receiving memantine. On the other hand, cardiac failure and deep vein thrombosis AEs were found to be more common in patients receiving memantine. The majority of reported cardiac and vascular AEs were reported more frequently in female patients. More cases of cardiac failure, cardiac arrest, and deep vein thrombosis were reported in females than males taking memantine, but bradycardia was more common in males than females.Conclusion: Healthcare professionals should be aware of the potential for cardiovascular AEs during treatment with antidementia medications and the possibility of sex differences in this regard. Memantine differs from cholinesterase inhibitors in terms of cardiovascular AEs, and there may be sex‐related differences in the proportion of these AEs.
- 12 November 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (11) , 2095-2120
Pharmacological Innovations in Space: Challenges and Future Perspectives
Purpose Since the first human experience in space, the interest in space research and medicine to explore universe is growing day by day. The extreme space conditions mainly radiation and microgravity effects on human physiology, antimicrobial susceptibility, and efficacy, safety, and stability of drugs. Therefore, the aim of this review is to address the impact of extreme space conditions, mainly microgravity and radiation, on human physiology and highlights the need for future approaches by evaluating the effectiveness of strategies to prevent or mitigate health problems. Methods Published papers and NASA technical documents were searched in Pubmed and Google Scholar databases using the keywords ‘‘antimicrobial susceptibility or drug resistance or drug stability or innovations or pharmacokinetic or pharmacodynamics’’ and ‘‘radiation or microgravity or space environments or space medicine or space pharmacy’' to prepare this review. Results In this review, the challenges regarding physiological effects and drug-related problems are examined through the evaluation of extreme conditions in space. Medications used in spaceflight are summarized, and the role of pharmacists specializing in space medicine is briefly explained. Last but not least, to overcome the aforementioned issues, novel approaches have been addressed, such as personalised treatments, development of space-resistant formulations and various microbial applications. Conclusions Further research in the space medicine is required to facilitate the safe and healthy travel of humans to the Moon, Mars and other extraterrestrial destinations. One bear in mind that space research will contribute not only to the exploration of the universe, but also to the advancement of health and technological discoveries on Earth.
- 12 November 2024
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (11) , 2095-2120
Pharmacological Innovations in Space: Challenges and Future Perspectives
Purpose Since the first human experience in space, the interest in space research and medicine to explore universe is growing day by day. The extreme space conditions mainly radiation and microgravity effects on human physiology, antimicrobial susceptibility, and efficacy, safety, and stability of drugs. Therefore, the aim of this review is to address the impact of extreme space conditions, mainly microgravity and radiation, on human physiology and highlights the need for future approaches by evaluating the effectiveness of strategies to prevent or mitigate health problems. Methods Published papers and NASA technical documents were searched in Pubmed and Google Scholar databases using the keywords ‘‘antimicrobial susceptibility or drug resistance or drug stability or innovations or pharmacokinetic or pharmacodynamics’’ and ‘‘radiation or microgravity or space environments or space medicine or space pharmacy’' to prepare this review. Results In this review, the challenges regarding physiological effects and drug-related problems are examined through the evaluation of extreme conditions in space. Medications used in spaceflight are summarized, and the role of pharmacists specializing in space medicine is briefly explained. Last but not least, to overcome the aforementioned issues, novel approaches have been addressed, such as personalised treatments, development of space-resistant formulations and various microbial applications. Conclusions Further research in the space medicine is required to facilitate the safe and healthy travel of humans to the Moon, Mars and other extraterrestrial destinations. One bear in mind that space research will contribute not only to the exploration of the universe, but also to the advancement of health and technological discoveries on Earth.
- Open Access
- 26 March 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (5) , 2949-2970
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
With 54 new drugs and seven cellular and gene therapy products, the approvals by the US Food and Drug Administration (FDA) recovered 2023 from the 2022 dent back to the levels of 2020–2021. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify four (7%) “first-in-indication,” 22 (36%) “first-in-class,” and 35 (57%) “next-in-class” drugs. By treatment area, rare diseases (54%) and cancer drugs (23%) were once again the most prevalent (and partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics). 2023 marks the approval of a first therapy based on CRISPR/Cas9 gene editing.
- 26 March 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (5) , 2949-2970
Open AccessA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
With 54 new drugs and seven cellular and gene therapy products, the approvals by the US Food and Drug Administration (FDA) recovered 2023 from the 2022 dent back to the levels of 2020–2021. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify four (7%) “first-in-indication,” 22 (36%) “first-in-class,” and 35 (57%) “next-in-class” drugs. By treatment area, rare diseases (54%) and cancer drugs (23%) were once again the most prevalent (and partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics). 2023 marks the approval of a first therapy based on CRISPR/Cas9 gene editing.